LAVA Therapeutics (NASDAQ:LVTX) Receives New Coverage from Analysts at JMP Securities

JMP Securities started coverage on shares of LAVA Therapeutics (NASDAQ:LVTXGet Rating) in a note issued to investors on Thursday, September 15th, The Fly reports. The firm set an “outperform” rating on the stock.

Separately, SVB Leerink upped their target price on LAVA Therapeutics to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, May 18th.

LAVA Therapeutics Stock Performance

Shares of NASDAQ LVTX traded down $0.10 during mid-day trading on Thursday, reaching $2.36. 1,088 shares of the company traded hands, compared to its average volume of 3,879. The company’s fifty day moving average is $2.54 and its two-hundred day moving average is $3.25. LAVA Therapeutics has a fifty-two week low of $2.28 and a fifty-two week high of $8.38.

About LAVA Therapeutics

(Get Rating)

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.

Featured Stories

The Fly logo

Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.